Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.34 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.34 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.34 |
| ▸ | PPM1B | O75688 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | GBA1 | P04062 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1296435 | 1.00 | PPARG (0.39) | PPARGMAPTADRB2ADRB1ADRB3 | |
| SCHEMBL1297209 | 0.96 | PPARG (0.37) | PPARGMAPTADRB2ADRB1ADRB3 | |
| SCHEMBL1297466 | 0.96 | PPARG (0.43) | PPARGMAPTADRB2ADRB1ADRB3 | |
| SCHEMBL1297809 | 0.95 | PPARG (0.36) | PPARGMAPT | |
| SCHEMBL1297658 | 0.95 | PPARG (0.36) | PPARGMAPT | |
| SCHEMBL1296705 | 0.95 | PPARG (0.36) | PPARGMAPT | |
| SCHEMBL1297784 | 0.95 | PPARG (0.36) | PPARGMAPT | |
| SCHEMBL1296945 | 0.94 | PPARG (0.38) | PPARGMAPTADRB2ADRB1ADRB3 | |
| SCHEMBL1297192 | 0.93 | GAA (0.39) | PPARGMAPTADRB2ADRB1ADRB3 | |
| SCHEMBL1297830 | 0.93 | PPARG (0.35) | PPARGMAPTADRB2ADRB1ADRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8822724-B2 | Method for producing carboxylic acid amide | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2014-09-02 | — | — | US | disclosed |
| EP-2599769-A1 | METHOD FOR PRODUCING CARBOXYLIC ACID AMIDE | Sumitomo Chemical Company Limited (JP) | 2013-06-05 | — | — | EP | disclosed |
| US-20130123505-A1 | METHOD FOR PRODUCING CARBOXYLIC ACID AMIDE | SUMITOMO CHEMICAL COMPANY, LIMITED | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123505-A1 | METHOD FOR PRODUCING CARBOXYLIC ACID AMIDE | HCAR2, NAAA, FAAH2 | PPARG 790/4885MAPT 3830/4885ADRB2 2203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.